Content

Past Issues

Download Magazine

Search

Subscribe

  • This field is for validation purposes and should be left unchanged.

Depression Linked to Poor Diabetes Self-Management

Depression Linked to Poor Diabetes Self-Management

Depression is more common among people with type 2 diabetes (T2D) than in those without the condition and is also associated with a greater risk for serious complications, possibly because depressed individuals with T2D tend to neglect their medication regimen.

In a paper published last December in the Journal of Diabetes and Its Complications, Einstein researchers led by Jeffrey Gonzalez, Ph.D., associate professor of medicine and of epidemiology & population health, explored the connection between depression and medication adherence among 376 low-income, racially diverse adults with poorly controlled T2D. All participants filled out questionnaires to assess symptoms of depression.

The 83 people (22 percent of the group) who tested positive for major depressive disorder had a nearly threefold increased risk for low medication adherence compared with nondepressed participants. Somewhat surprisingly, adherence was also a problem for individuals who reported feeling fatigued but were not depressed: They were 77 percent more likely than nonfatigued individuals to have low medication adherence.

“We observed a significant relationship between depression and medication nonadherence in our study,” Dr. Gonzalez says. “In addition, fatigue may have a connection to the risk for nonadherence that is independent of depression’s role. These results suggest that health providers should be alert to the presence and severity of depression as well as the presence of fatigue when trying to improve medication adherence among their patients with type 2 diabetes.”

More From Einstein

Class of 2024 Celebrates Match Day
Einstein Community Enjoys Pi Day
Graduate Students Win Marmur Award
Empowering Einstein Women in Science
Einstein Secures $192M in NIH Grants
Training the Next Cancer Researchers
Bringing a Novel Drug to Market
A Promise to Rwandan Genocide Survivors